Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
University Hospital, Brest
Astex Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
Amgen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Pfizer
Array BioPharma
Baylor College of Medicine
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Prothena Biosciences Ltd.
Ohio State University Comprehensive Cancer Center
Seagen Inc.
Seagen Inc.
AVEO Pharmaceuticals, Inc.
Rennes University Hospital
Fenwal, Inc.
Washington University School of Medicine